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Abstract
Background: Pediatric germ cell tumors account for approximately 3.5 % of all childhood cancers for children
under the age of 15 years. Up to one-third are extragonadal neoplasms. Germ cell tumors are a heterogeneous
group of malignant tumors with a wide variety of histopathological features. Yolk sac tumor is the predominant
variant in newborns and younger children. We report for the first time, the presentation of a primary yolk sac tumor
in the abdominal wall of a small child.
Case presentation: An 18-month-old white girl underwent resection of a small, round subcutaneous lump (1.5×1.
3×0.8 cm) of the abdominal wall in her right hypochondriac region. The histopathology was compatible with yolk
sac tumor. Her alpha-fetoprotein was initially elevated but normalized after the resection. Magnetic resonance
imaging of her abdomen was normal. The surgeon decided to observe and follow her alpha-fetoprotein level
closely. One year after resection a local recurrence appeared and her alpha-fetoprotein rose to 58 ng/mL. The
surgeon performed a wide resection of the lesion with normalization of her alpha-fetoprotein. Follow-up consisted
of measuring alpha-fetoprotein, clinical evaluation, and abdominal ultrasound.
Conclusions: Clinicians should be aware that a yolk sac tumor can present in an unusual extragonadal place, for
example in this case it was subcutaneous. In some cases, conservative treatment can be carried out with careful
monitoring of the patient and their alpha-fetoprotein.
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Background
Pediatric germ cell tumors (GCTs) account for approxi-
mately 3.5 % of all childhood cancers for children under
the age of 15 years. Between the ages 15 and 19 the fre-
quency goes up to 16 %. Up to one-third are extragonadal
neoplasms and the most common sites are the sacrococ-
cygeal or retroperitoneal region, and the pineal gland. The
incidence of extragonadal tumors varies widely by age
(higher in younger age) and gender (more often in girls at
a younger age, while intracranial/intraspinal tumors are
more common in boys at an older age) [1].
The only known risk factor for extragonadal GCTs is
the presence of Klinefelter syndrome (47,XXY karyo-
type). In that case, there is a 50-fold increased risk of de-
veloping mediastinal GCTs in early adolescence [2, 3].
GCTs are a heterogeneous group of malignant tumors
with a wide variety of histopathological features. Yolk
sac tumor is the predominant variant in newborns and
younger children, while later in life a wide range of
histologic subtypes are seen. Yolk sac tumors have a
microcystic reticular pattern and are cytokeratin-
positive. Alpha-fetoprotein (αFP) expression is character-
istic and can be used for diagnosis and monitoring of
therapy. To the best of our knowledge, this is the first
report of the presentation of a primary yolk sac tumor in
the abdominal wall of a small child. After resection of
the tumor, close monitoring was conducted, without any
adjuvant chemotherapy.
Case presentation
An 18-month-old white girl underwent resection of a
small, round subcutaneous lump (1.5×1.3×0.8 cm) of the
abdominal wall in her right hypochondriac region. The
tumor was connected to her skin and had the macro-
scopic appearance of a pilomatrixoma (epithelioma of
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Malherbe). Surprisingly the histopathology was compat-
ible with yolk sac tumor, showing a microcystic reticular
pattern (Fig. 1) with positive staining for cytokeratin 8 as
well as cytoplasmic granular staining of αFP (Fig. 2). The
resection borders were not completely clear from tumor
tissue: stage II according to the Pediatric Oncology
Group (POG)/Children’s Cancer Study Group (CCG)
staging for malignant extragonadal GCT [4]. Her αFP
was 57 ng/mL 3 weeks after resection and dropped to 15
ng/mL 1 month later; her beta subunit of human chori-
onic gonadotropin (ßHCG) was normal. An magnetic
resonance imaging (MRI) of her abdomen was normal.
The surgeon decided to observe and follow our patient’s
αFP closely because of the lack of radiological evidence
of the presence of a tumor and the decline in her αFP.
Her αFP remained stable in the first months. One year
after resection a local recurrence (1.1 cm, Fig. 3) ap-
peared with an increase in her αFP to 29 ng/mL. An
MRI of her head, neck, thorax, and abdomen did not
show any other masses. The surgeon performed a wide
resection of the lesion. The pathology report confirmed
the previous findings; the borders were free of tumor tis-
sue. Because the tumor was completely removed with
normalization of her αFP (on the day of surgery her αFP
was 58 ng/mL, 10 days later 12 ng/mL, 1 month postop-
erative 8 ng/mL) and there was no evidence of any other
tumor masses, the management was expectative. The
first year post-resection was uneventful without clinical
signs of local recurrence and with normal monthly αFP
level. An abdominal ultrasound, 1 year after resection,
did not reveal a recurrence. Follow-up continued meas-
uring αFP on a regular basis with gradually extending in-
tervals (every 3 months in the second year, every 6
months in the third year and once a year in the fourth
and fifth year). Clinical evaluation and abdominal
ultrasound 5 years after the second resection showed a
full tumor-free remission (Fig. 4). She was discharged
from systematic follow-up.
Discussion
GCTs consist of neoplastic cells arising from germ line
cells (egg or sperm). They occur either in the testis or
Fig. 1 Yolk sac tumor with a reticular pattern formed by a loose
meshwork of spaces (10×)
Fig. 2 Yolk sac tumor with strong cytoplasmic positivity for alpha-
fetoprotein
Fig. 3 Ultrasound of the abdominal wall showing a subcutaneous
oval-shaped nodule, hyporeflective, and without clear margins.
Abdominal magnetic resonance imaging (axial oblique T1-weighted
with contrast) with a contrast-captivating nodule in the right
abdominal wall
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ovary, or outside the gonads. The extragonadal location
is caused by either malignant transformation of aber-
rantly migrated primordial germ cell misplaced during
the embryogenesis, or by a metastatic lesion of an un-
detected primary gonadal GCT not yet macroscopically
visible or already spontaneously regressed. Extragonadal
yolk sac tumors are rare and typically occur in midline
locations, other sites have rarely been described [5]. Yolk
sac tumors most often present in the first years of life
and rarely with metastatic disease at diagnosis [6]. While
age seems not to be a predictive factor, some authors de-
scribe the elevation of αFP to be prognostically import-
ant [7]. The αFP levels appear to correlate with the
pathologic grade of retroperitoneal teratomas [8].
Without appropriate treatment, the tumor is highly ag-
gressive, but with the combined treatment of surgery
and adjuvant multi-agent platinum-based chemotherapy,
a survival rate greater than 90 % can be achieved. The
currently used regimens have comparable efficacy: PEI
(cisplatin, etoposide, ifosfamide); carboPEI (carboplatin,
PEI); BEP (bleomycin, etoposide, cisplatin); and carbo-
platin, etoposide, bleomycin [9].
Billmire et al. studied 25 children with malignant
GCTs of the abdomen and retroperitoneum as the pri-
mary site and examined survival and event-free survival
rates using high-dose or standard-dose cisplatin-based
combination chemotherapy and surgical resection for
these patients [10]. Most tumors were of advanced stage
at diagnosis and in 15 patients histology showed pure
yolk sac tumor. Of the 25 patients, four patients had
their primary site located at the abdominal wall [10].
Maubec et al. reported an overview of primary skin
GCTs, 16 of the 19 patients were children, and a mature
teratoma was the most frequent diagnosis [11].
Tedgϋndϋz et al. described a 3-year-old girl with a sub-
cutaneous paraspinal yolk sac tumor with metastatic dis-
ease located in the scar tissue at the surgical site and
lumbar vertebrae. She received chemotherapy (cisplatin,
etoposide, and bleomycin) and has been in remission for
several years [12]. No other child with yolk sac tumor of
the skin has been reported in the literature.
In yolk sac tumors, the tumor marker αFP is extremely
sensitive for diagnosis and in follow-up after the appro-
priate treatment has been given [13]. αFP is an import-
ant serum binding protein in the fetus and is produced
in the first trimester of fetal development by the yolk
sac, afterwards by the fetal liver, and is gradually
replaced by albumin. The αFP levels are usually highly
elevated at birth with a significant variation in values
among babies [14]. The half-life of αFP is approximately
5 to 6 days and normal adult levels (<10 IU/l) are
achieved by the age of 2 years. Even then a wide vari-
ation in levels is observed [14] and some suggest that a
mild elevation in αFP should not be used as the sole cri-
terion to initiate or continue chemotherapy [15]. There-
fore, in the first 2 years of life, αFP levels should be
compared with age-related normal values. Serial mea-
surements are necessary for optimal treatment decision.
Most relapses occur within the first 2 years after diagno-
sis. Failure to normalize or a rise in the αFP level indi-
cates a recurrence or incomplete resection of the yolk
sac tumor [16], even before this can be shown by im-
aging methods.
αFP is regarded as a characteristic tumor marker of
malignant GCTs and epithelial liver tumors. It is not
tumor-specific. Elevated αFP in the serum of a child is
also associated with benign conditions, for example hep-
atic disorders, hereditary disorders (for example ataxia
telangiectasia, tyrosinemia type 1), systemic lupus
erythematosus, and other malignant tumors (for ex-
ample hepatoblastoma, hepatocellular carcinoma, pan-
creaticoblastoma, retinoblastoma) [17].
In regards of the patient presented, after the first re-
section, it was decided to observe her closely and not
perform a wide resection. After local recurrence with an
elevated αFP, a wide resection was done. No distant pri-
mary disease was found. Despite the availability of highly
effective chemotherapy, we decided to observe. If the
tumor reoccurs, then effective therapy can still be given.
Due to the localization and the elevation of αFP we
could easily perform intensive surveillance by monthly
measurement of her αFP and yearly ultrasound of her
abdomen (watch-and-wait strategy).
Conclusions
We describe the first report of an 18-month-old girl di-
agnosed with a yolk sac tumor subcutaneously. A year
after resection, she presented with local recurrence,
which was treated with a wide resection only. Five years
of follow-up did not reveal signs of local recurrence or dis-
tant disease. It is important that clinicians are aware that
yolk sac tumor can present in an unusual extragonadal
Fig. 4 The course of alpha-fetoprotein in time (months) after
the first resection. The arrow represents the second resection.
αFP alpha-fetoprotein
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place. In some cases, conservative treatment can be carried
out with careful monitoring of the patient and their αFP.
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